EX-99
3
ex99-1f.txt
EX-99.1
EXHIBIT 99.1
IRIS CLOSES ACQUISITION OF QUIDEL'S URINALYSIS BUSINESS
CHATSWORTH, Calif.--June 6, 2005--IRIS International, Inc. (NASDAQ: IRIS), a
manufacturer and marketer of automated IVD urinalysis systems and medical
devices used in hospitals and clinical reference laboratories worldwide, today
announced the closing of its previously announced acquisition of the urinalysis
business segment of Quidel Corporation (NASDAQ: QDEL) for $500,000 in cash by
IRIS' wholly owned subsidiary, IRIS Deutschland GmbH.
"The acquisition of the UrinQuick(R) Semi-Automated Urine Chemistry Analyzer and
related technology including UrinChek(R) consumable test strips, opens a new
market for IRIS that will complement our family of fully automated iQ(R)200
Urine Microscopy Analyzers. The business integration is proceeding as scheduled
and, we look forward to growing and enhancing our new urine chemistry business,"
stated President and Chief Executive Officer Cesar Garcia.
The UrinQuick is a semi-automated benchtop instrument for rapid analysis that
will be offered to IRIS' international customers, except those in Japan. IRIS
already has reciprocal distribution agreements for urine chemistry and
microscopy analyzers covering the U.S. and Japan with its Japanese partner,
Arkray, Inc.
THE COMPANY
IRIS International, Inc. (www.proiris.com) is a leader in automated urinalysis
technology with systems in major medical institutions throughout the world. The
Company's newest generation iQ(R)200 Automated Urine Microscopy Analyzer,
utilizing image flow cytometry, patented Automated Intelligent Microscopy (AIM)
technology and neural network-based particle recognition, achieves a significant
reduction in the cost and time-consuming steps involved in manual microscopic
analysis. The Company's StatSpin(R) subsidiary, based in Norwood, Mass.,
manufactures innovative centrifuges and blood analysis products. Advanced
Digital Imaging Research, LLC (ADIR), based near Houston, Texas, is the
Company's imaging research and development subsidiary.
SAFE HARBOR PROVISION
This news release contains forward-looking statements made in reliance upon the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include, but are not limited to, the Company's views
on future commercial revenues, market growth, capital requirements, and new
product introductions, and are generally identified by phrases such as "thinks,"
"anticipates", "believes", "estimates", "expects", "intends", "plans", and
similar words. Forward-looking statements are not guarantees of future
performance and are inherently subject to uncertainties and other factors which
could cause actual results to differ materially from the forward-looking
statement. These statements are based upon, among other things, assumptions made
by, and information currently available to, management, including management's
own knowledge and assessment of the Company's industry, competition and capital
requirements. Other factors and uncertainties that could affect the Company's
forward-looking statements include, among other things, the following: the
acceptance by customers of our new iQ(R)200 product platform, our substantial
expansion of international sales and our reliance on key suppliers, the
potential need for changes in long-term strategy in response to future
developments; future advances in diagnostic testing methods and procedures, as
well as potential changes in government regulations and healthcare policies,
both of which could adversely affect the economics of the diagnostic testing
procedures automated by the Company's products; rapid technological change in
the microelectronics and software industries; and increasing competition from
imaging and non-imaging based in-vitro diagnostic products. The Company refers
interested persons to its most recent Annual Report on Form 10-K and its other
SEC filings for a description of additional uncertainties and factors that may
affect forward-looking statements. The Company assumes no duty to update its
forward-looking statements.
----------
CONTACT:
IRIS International, Inc.
Cesar M. Garcia, 818-709-1244 x123
or
The Wall Street Group, Inc.
Ron Stabiner, 212-888-4848

EX - 99 3 ex99 - 1f . txt EX - 99 . 1 EXHIBIT 99 . 1 IRIS CLOSES ACQUISITION OF QUIDEL 'S URINALYSIS BUSINESS CHATSWORTH , Calif . -- June 6 , 2005 -- IRIS International , Inc . ( NASDAQ : IRIS ) , a manufacturer and marketer of automated IVD urinalysis systems and medical devices used in hospitals and clinical reference laboratories worldwide , today announced the closing of its previously announced acquisition of the urinalysis business segment of Quidel Corporation ( NASDAQ : QDEL ) for $ 500,000 in cash by IRIS ' wholly owned subsidiary , IRIS Deutschland GmbH . " The acquisition of the UrinQuick ( R ) Semi - Automated Urine Chemistry Analyzer and related technology including UrinChek ( R ) consumable test strips , opens a new market for IRIS that will complement our family of fully automated iQ ( R ) 200 Urine Microscopy Analyzers . The business integration is proceeding as scheduled and , we look forward to growing and enhancing our new urine chemistry business , " stated President and Chief Executive Officer Cesar Garcia . The UrinQuick is a semi - automated benchtop instrument for rapid analysis that will be offered to IRIS ' international customers , except those in Japan . IRIS already has reciprocal distribution agreements for urine chemistry and microscopy analyzers covering the U . S . and Japan with its Japanese partner , Arkray , Inc . THE COMPANY IRIS International , Inc . ( www.proiris.com ) is a leader in automated urinalysis technology with systems in major medical institutions throughout the world . The Company 's newest generation iQ ( R ) 200 Automated Urine Microscopy Analyzer , utilizing image flow cytometry , patented Automated Intelligent Microscopy ( AIM ) technology and neural network - based particle recognition , achieves a significant reduction in the cost and time - consuming steps involved in manual microscopic analysis . The Company 's StatSpin ( R ) subsidiary , based in Norwood , Mass . , manufactures innovative centrifuges and blood analysis products . Advanced Digital Imaging Research , LLC ( ADIR ) , based near Houston , Texas , is the Company 's imaging research and development subsidiary . SAFE HARBOR PROVISION This news release contains forward - looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include , but are not limited to , the Company 's views on future commercial revenues , market growth , capital requirements , and new product introductions , and are generally identified by phrases such as " thinks , " " anticipates " , " believes " , " estimates " , " expects " , " intends " , " plans " , and similar words . Forward - looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward - looking statement . These statements are based upon , among other things , assumptions made by , and information currently available to , management , including management 's own knowledge and assessment of the Company 's industry , competition and capital requirements . Other factors and uncertainties that could affect the Company 's forward - looking statements include , among other things , the following : the acceptance by customers of our new iQ ( R ) 200 product platform , our substantial expansion of international sales and our reliance on key suppliers , the potential need for changes in long - term strategy in response to future developments ; future advances in diagnostic testing methods and procedures , as well as potential changes in government regulations and healthcare policies , both of which could adversely affect the economics of the diagnostic testing procedures automated by the Company 's products ; rapid technological change in the microelectronics and software industries ; and increasing competition from imaging and non - imaging based in - vitro diagnostic products . The Company refers interested persons to its most recent Annual Report on Form 10 - K and its other SEC filings for a description of additional uncertainties and factors that may affect forward - looking statements . The Company assumes no duty to update its forward - looking statements . ---------- CONTACT : IRIS International , Inc . Cesar M . Garcia , 818 - 709 - 1244 x123 or The Wall Street Group , Inc . Ron Stabiner , 212 - 888 - 4848
O O O O O O O O O O O O O O O O O O B-Parties.BUYING_COMPANY O O O B-Parties.SELLING_COMPANY O O O O O O O O O O O O O B-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY I-Parties.BUYING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O B-Parties.SELLING_COMPANY I-Parties.SELLING_COMPANY O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O